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You are a medical student in clinic asked to 
see a 42-year-old man with a past medical 
history of anxiety. He is presenting with 
concerns about progressive balding and 
weight gain. Recently, he came across an 
internet advertisement suggesting his 
symptoms may be linked to a low 
testosterone level. He asks you to provide 
him with a testosterone prescription. What 
should medical trainees know about 
advertising of pharmaceutical products to 
help patients assess the quality of the 
information that they have received? 
Current Canadian Regulations  
Under the Food and Drug Regulations in Canada, 
Direct-to-Consumer Advertising of Prescription 
Medications (DTCA) is generally prohibited.1 
However, for a variety of reasons, Canadians are 
increasingly exposed. A review of complaints about 
DTCA to Health Canada shows that through loopholes 
in the interpretation of legislation and poor 
enforcement by Health Canada, pharmaceutical 
companies have used a variety of different tactics to 
advertise their products.2 One of them is “reminder 
ads” wherein companies can advertise their brand 
without naming the purpose of their product, simply 
requesting consumers to “ask your doctor.” Another 
strategy termed “help seeking” urges people to visit 
their doctor to discuss a certain medical condition, 
without identifying the brand or product. In reality, 
the pharmaceutical industry combines these 
maneuvers with blatant violations of regulations, 
knowing the profit benefit outweighs any possible 
sanctions or fines. A Canadian example is Diane-35, a 
drug approved for treatment of severe acne, but 
where the company used marketing techniques that 
implied it could be used for off-label contraception 
and suffered few repercussions for doing so.  
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In an increasingly globalized world, borders are in 
many ways beginning to fade. This holds especially 
true for DTCA, through which broadcast and online 
use could expose consumers to advertisements that 
are not bound by Canada’s regulation. Many 
Canadians already watch US television broadcasts, 
which contain many poorly-regulated pharmaceutical 
advertisements.3 With digital DTCA on the rise and 
regulatory responses several steps behind, online 
platforms are a popular medium for industry 
investments.4 Expenditure on internet-based DTCA is 
growing, whereas all other categories have been 
experiencing steady expenditure declines, suggesting 
a strategic shift in keeping with the evolution of digital 
health.5 More than ever, Canadians are vulnerable to 
DTCA, and our physicians must be trained to know 
how to respond when patients make requests based 
on ads that they have seen. 
Evidence regarding DTCA  
While it has been suggested that DTCA may have 
benefits such as identifying and encouraging 
treatment for diseases, improving medication 
compliance, and promoting health education, the 
bulk of prevailing evidence indicates that these 
effects are speculative and do not justify harms to 
public health.6 DTCA misleads consumers by 
obscuring side effects and harms, concealing details 
about products that may put them in a negative light, 
and instead presenting information to cast products 
or health conditions of interest in a positive way.7 
Patients who encounter these biased advertisements 
are likely to present to their physicians with questions 
and requests, and physicians in turn are more likely to 
order tests or prescribe medications consistent with 
the advertising.8 This can lead to overprescribing, 
disease mongering, unnecessary medication use, and 
suboptimal treatment, all of which could have 
dangerous consequences.9 
What is taught in medical school about DTCA 
To our knowledge, no Canadian medical school 
dedicates a formalized curriculum component 
specific to DTCA. However, Canadian medical schools 
do have policies towards conflicts of interest; these 
govern direct interactions between students and 
pharmaceutical companies as well as indirect 
interactions between students and lecturers who 
have a relationship with pharmaceutical companies.10 
These policies, however, range widely in 
comprehensiveness across the medical schools – 
within Canada, different medical schools afford 
varying levels of protection to students about 
conflicts of interest that may impact the education 
that they are receiving.  
Taken together, this lack of a strong, uniform focus on 
policies about conflicts of interest suggests that any 
teaching regarding DTCA is currently insufficient and 
that the content is variable among, and likely even 
within, schools. This is a cause for concern because 
medical students will likely encounter DTCA early in 
medical school while interacting with patients. For 
example, students are frequently reminded that their 
future patients will likely have “Googled” their 
symptoms prior to an appointment. Up to 70% of 
Canadians search their medical symptoms online 
prior to seeing a doctor.11,12 If this is the case, patients 
will have undoubtedly been subjected to DTCA, as 
eDTCA is one of the fastest growing forms of DTCA. 
Data tracking is a growing phenomenon and is re-
shaping the advertising field entirely. As such, 
internet DTCA is more customized than ever, with 
advertisements tailored to patients’ specific internet 
browsing history – one click at a time.5  
Revisiting our introductory case 
Does the case presented above in the introduction 
warrant testosterone investigation? A 2015 Canadian 
clinical practice guideline on testosterone deficiency 
and management does not provide a clear answer.13 
When clinical guidelines are unclear or potentially 
ambiguous, physicians can be swayed in favour of 
marketed/advertised products, especially in the face 
of interest from a patient. This 42-year-old patient’s 
symptoms of weight gain and balding could be 
explained by a host of medical, environmental, and 
genetic factors. In the case of testosterone 
advertising in the US between 2000 and 2011, DTCA 
was associated with an increase of more than 250% 
in testosterone prescriptions for males.14 
Testosterone prescriptions were often initiated for 
non-specific symptoms and even when patients did 
not meet the classical diagnostic criteria for 
hypogonadism. Additionally, physicians often 
deviated from established clinical guidelines by 
prescribing testosterone without prior serum 
testing.15 Like most other drugs, testosterone is not 
an inert substance and has been associated with 
adverse outcomes including myocardial infarction 
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and stroke.16 We should therefore always remain 
vigilant about our prescribing practices, an approach 
medical students need to learn. 
What medical trainees should know 
In the situation where a patient asks about an 
advertised pharmaceutical product, the medical 
trainee should remember a useful mnemonic, “DTCA” 
to structure their approach. 
D – Deliberate  
Take a step back and consider how DTCA can 
influence your own prescribing practices. Be wary 
that interactions with pharmaceutical companies 
have been consistently shown to alter the prescribing 
patterns of physicians, despite the majority denying 
the capacity to be influenced.17 
T – Tune in 
Use a patient-centred stance to actively listen to the 
patient and explore the underpinnings of their 
request. A strong patient-physician relationship is 
critical in promoting a candid environment where 
patients will feel comfortable in discussing and 
learning about the contents of DTCA.  
C – Counsel  
Counsel the patient using an objective approach, 
taking into consideration the potential benefits, 
harms, and side effects. Explain that healthcare 
providers have a fiduciary duty to patients alone, and 
that pharmaceutical companies do not.  
A – Advise  
Offer your perspective and suggest alternative 
options to present the patient with the necessary 
information to make an informed decision. After all, 
the majority of patients want their physicians to help 
them in understanding the contents of DTCA.18 
When a patient requests a medication or test that is 
not in their best interest, it is most advantageous to 
use strategies that reinforce and validate your 
patient, while also negotiating the most suitable 
option. First is the “substitution strategy,” which 
reframes the diagnosis or offers an alternative 
treatment. If this fails, the “contingency strategy” can 
offer a trial of the evidence-based treatment strategy 
with an agreed-upon definition of success, while 
agreeing to switch to the patient’s preference after a 
period of time if the evidence-based treatment is 
unsuccessful.19 
Call to educators 
Integration of an approach to a patient with questions 
about diagnosis and treatment generated by DTCA 
into all levels of medical training is increasingly 
important. The same principles hold true for medical 
devices, genetic testing, and other health products 
that are directly advertised to patients.  
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